Form 4: Director Timothy P. Walbert Receives Odyssey Stock Options

Director Timothy P. Walbert was granted 27,393 stock options in Odyssey Therapeutics, Inc. with an exercise price of $18.00.

Summary

• Director Timothy P. Walbert received a grant of 27,393 stock options on May 7, 2026.
• The options have an exercise price of $18.00 per share.
• The options are scheduled to vest in full on May 7, 2027, contingent upon continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is subject to the Reporting Person's continued service, creating a dependency on retention.

Future Outlook

The options vest in one year, indicating a focus on director retention and long-term commitment to the company's performance.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership alignment with clinical and commercial milestones.

Comparison to Industry Standards

• The use of time-based vesting for director options is consistent with standard corporate governance practices in the U.S. biotech industry.
• Grant sizes for independent directors typically align with peer-group compensation benchmarks for mid-stage clinical companies.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options on May 7, 2027.

Key Dates

Keywords

Odyssey Therapeutics, ODTX, Form 4, Insider Trading, Stock Options, Director Compensation